162 related articles for article (PubMed ID: 35984852)
1. Utilisation of semiconductor sequencing for detection of actionable fusions in solid tumours.
Loddo M; Hardisty KM; Llewelyn A; Haddow T; Thatcher R; Williams G
PLoS One; 2022; 17(8):e0246778. PubMed ID: 35984852
[TBL] [Abstract][Full Text] [Related]
2. Utilisation of semiconductor sequencing for the detection of predictive biomarkers in glioblastoma.
Williams G; Llewelyn A; Thatcher R; Hardisty KM; Loddo M
PLoS One; 2022; 17(3):e0245817. PubMed ID: 35324914
[TBL] [Abstract][Full Text] [Related]
3. Targeted next generation sequencing of MLH1-deficient, MLH1 promoter hypermethylated, and BRAF/RAS-wild-type colorectal adenocarcinomas is effective in detecting tumors with actionable oncogenic gene fusions.
Vaňková B; Vaněček T; Ptáková N; Hájková V; Dušek M; Michal M; Švajdler P; Daum O; Daumová M; Michal M; Mezencev R; Švajdler M
Genes Chromosomes Cancer; 2020 Oct; 59(10):562-568. PubMed ID: 32427409
[TBL] [Abstract][Full Text] [Related]
4. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy.
Hsiao SJ; Zehir A; Sireci AN; Aisner DL
J Mol Diagn; 2019 Jul; 21(4):553-571. PubMed ID: 31075511
[TBL] [Abstract][Full Text] [Related]
5. Testing algorithm for identification of patients with TRK fusion cancer.
Penault-Llorca F; Rudzinski ER; Sepulveda AR
J Clin Pathol; 2019 Jul; 72(7):460-467. PubMed ID: 31072837
[TBL] [Abstract][Full Text] [Related]
6. Comparison of RNA-Based Next-Generation Sequencing Assays for the Detection of NTRK Gene Fusions.
Park HJ; Baek I; Cheang G; Solomon JP; Song W
J Mol Diagn; 2021 Nov; 23(11):1443-1451. PubMed ID: 34756276
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA.
Supplee JG; Milan MSD; Lim LP; Potts KT; Sholl LM; Oxnard GR; Paweletz CP
Lung Cancer; 2019 Aug; 134():96-99. PubMed ID: 31320002
[TBL] [Abstract][Full Text] [Related]
8. Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers.
Farago AF; Demetri GD
Future Oncol; 2020 Mar; 16(9):417-425. PubMed ID: 32129093
[TBL] [Abstract][Full Text] [Related]
9. Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib.
Awada A; Berghmans T; Clement PM; Cuppens K; De Wilde B; Machiels JP; Pauwels P; Peeters M; Rottey S; Van Cutsem E
Crit Rev Oncol Hematol; 2022 Jan; 169():103564. PubMed ID: 34861380
[TBL] [Abstract][Full Text] [Related]
10. Identifying patients with NTRK fusion cancer.
Solomon JP; Benayed R; Hechtman JF; Ladanyi M
Ann Oncol; 2019 Nov; 30 Suppl 8():viii16-viii22. PubMed ID: 32223934
[TBL] [Abstract][Full Text] [Related]
11. High-throughput diagnostic profiling of clinically actionable gene fusions in lung cancer.
Pfarr N; Stenzinger A; Penzel R; Warth A; Dienemann H; Schirmacher P; Weichert W; Endris V
Genes Chromosomes Cancer; 2016 Jan; 55(1):30-44. PubMed ID: 26394895
[TBL] [Abstract][Full Text] [Related]
12. [NTRK Fusions: A new way of treatment for gastro-intestinal tumor?].
Ouali K; Pellat A; Cohen R; Svrcek M; Penault-Llorca F; André T
Bull Cancer; 2020 Apr; 107(4):447-457. PubMed ID: 32067719
[TBL] [Abstract][Full Text] [Related]
13. TRK Inhibition: A New Tumor-Agnostic Treatment Strategy.
Kummar S; Lassen UN
Target Oncol; 2018 Oct; 13(5):545-556. PubMed ID: 30276762
[TBL] [Abstract][Full Text] [Related]
14. Emerging Targeted Therapy for Tumors with
Kheder ES; Hong DS
Clin Cancer Res; 2018 Dec; 24(23):5807-5814. PubMed ID: 29986850
[TBL] [Abstract][Full Text] [Related]
15. Detection of gene mutations and gene-gene fusions in circulating cell-free DNA of glioblastoma patients: an avenue for clinically relevant diagnostic analysis.
Palande V; Siegal T; Detroja R; Gorohovski A; Glass R; Flueh C; Kanner AA; Laviv Y; Har-Nof S; Levy-Barda A; Viviana Karpuj M; Kurtz M; Perez S; Raviv Shay D; Frenkel-Morgenstern M
Mol Oncol; 2022 May; 16(10):2098-2114. PubMed ID: 34875133
[TBL] [Abstract][Full Text] [Related]
16. The Diagnostic Value of Pan-Trk Expression to Detect Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion in CNS Tumours: A Study Using Next-Generation Sequencing Platform.
Mohamed F; Kurdi M; Baeesa S; Sabbagh AJ; Hakamy S; Maghrabi Y; Alshedokhi M; Dallol A; Halawa TF; Najjar AA; Fdl-Elmula I
Pathol Oncol Res; 2022; 28():1610233. PubMed ID: 35295612
[No Abstract] [Full Text] [Related]
17. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
[TBL] [Abstract][Full Text] [Related]
18. Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion.
Filippi R; Depetris I; Satolli MA
Expert Opin Pharmacother; 2021 Apr; 22(6):677-684. PubMed ID: 33576301
[No Abstract] [Full Text] [Related]
19. NTRK fusions in osteosarcoma are rare and non-functional events.
Ameline B; Saba KH; Kovac M; Magnusson L; Witt O; Bielack S; Nathrath M; Nord KH; Baumhoer D
J Pathol Clin Res; 2020 Apr; 6(2):107-112. PubMed ID: 32022484
[TBL] [Abstract][Full Text] [Related]
20. Identifying patients with NTRK fusion cancer.
Solomon JP; Benayed R; Hechtman JF; Ladanyi M
Ann Oncol; 2019 Nov; 30(Suppl_8):viii16-viii22. PubMed ID: 31738428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]